CCCC
HealthcareC4 Therapeutics, Inc.
$2.03
+$0.10 (+5.18%)
Jan 5, 2026
Price History (1Y)
Analysis
C4 Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $196.74 million and approximately 110 employees, the company's scale is modest compared to industry giants. Financially, C4 Therapeutics has reported significant losses with a net income (TTM) of -$119,081,000, EBITDA of -$117,042,000, and free cash flow of -$54,987,124. The gross margin stands at -271.2%, operating margin at -210.9%, and profit margin is 0.0%. Returns on equity and assets are also negative at -60.0% and -23.2%, respectively. The company's balance sheet shows $61.46 million in debt against $191.88 million in cash, resulting in a debt-to-equity ratio of 39.81. The company's valuation metrics are as follows: price to book is 0.98, price to sales is 6.53, and EV/EBITDA is -0.48. The forward P/E is -1.58, indicating significant losses in the recent past. Revenue growth has been negative at -26.9% year-over-year, while earnings growth data is not available. Dividend information is also unavailable, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $196.74M
- P/E Ratio
- N/A
- 52-Week High
- $4.22
- 52-Week Low
- $1.08
- Avg Volume
- 1.86M
- Beta
- 2.94
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 110